Tendai Mugwagwa

Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis

Tendai Mugwagwa, Benjamin A. Abramoff, Siddharth Karanth, Tram Nham et autres

High-risk patients with COVID-19 remained at elevated risk of severe outcomes in the Omicron era, even after receiving multiple vaccine doses. We report the Omicron-era healthcare resource utilization (HCRU) and cost burden of COVID-19 among commercially insured, oral antiviral therapy-eligible patients at …

Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis

Tendai Mugwagwa, Benjamin A. Abramoff, Siddharth Karanth, Tram Nham et autres

High-risk patients with COVID-19 remained at elevated risk of severe outcomes in the Omicron era, even after receiving multiple vaccine doses. We report the Omicron-era healthcare resource utilization (HCRU) and cost burden of COVID-19 among commercially insured, oral antiviral therapy-eligible patients at …

Supplementary Material for social care resource utilisation and costs associated with community- acquired COVID-19 infections among antiviral eligible adults at high risk of progressing to severe COVID-19: a matched cohort study in North-West London

Tendai Mugwagwa, Alejandra Castanon, Mohammad Ashraf Chaudhary, Jennifer K Quint et autres

This dataset contains code lists (MS excel files) for identifying populations at high risk of progressing to severe COVID-10 and eligible for antiviral therapy according to National Institute for Health and Care Excellence (NICE), Haute Autorité de Santé (HAS) guideline and U.S. …

Supplementary Material for social care resource utilisation and costs associated with community- acquired COVID-19 infections among antiviral eligible adults at high risk of progressing to severe COVID-19: a matched cohort study in North-West London

Tendai Mugwagwa, Alejandra Castanon, Mohammad Ashraf Chaudhary, Jennifer K Quint et autres

This dataset contains code lists (MS excel files) for identifying populations at high risk of progressing to severe COVID-10 and eligible for antiviral therapy according to National Institute for Health and Care Excellence (NICE), Haute Autorité de Santé (HAS) guideline and U.S. …

Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis

Tendai Mugwagwa, Benjamin A. Abramoff, Siddharth S. Karanth, Tram Nham et autres

BACKGROUND AND AIM: High-risk patients with COVID-19 remained at elevated risk of severe outcomes in the Omicron era, even after receiving multiple vaccine doses. We report the Omicron-era healthcare resource utilization (HCRU) and cost burden of COVID-19 among commercially insured, oral antiviral …

us (code pays fourni par la source)

Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review

Tendai Mugwagwa, Jose Marcano Belisario, Louise Hartley, Nguyen Thi Nhan Phan et autres

Nirmatrelvir/ritonavir (NMV/r)i is an antiviral drug indicated for the treatment of patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk of progressing to severe disease. We performed an updated economic systematic literature review (eSLR) of NMV/r to …

Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review

Tendai Mugwagwa, José S Marcano Belisario, Louise Hartley, Nhu-y Phan et autres

Aims Nirmatrelvir/ritonavir (NMV/r)Footnotei is an antiviral drug indicated for the treatment of patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk of progressing to severe disease. We performed an updated economic systematic literature review (eSLR) of NMV/r …

us (code pays fourni par la source)

Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review

Tendai Mugwagwa, Jose Marcano Belisario, Louise Hartley, Nguyen Thi Nhan Phan et autres

Nirmatrelvir/ritonavir (NMV/r)i is an antiviral drug indicated for the treatment of patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk of progressing to severe disease. We performed an updated economic systematic literature review (eSLR) of NMV/r to …

Potential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective

Jennifer Benner, J. H. Lee, Laura Cianciolo, Tendai Mugwagwa et autres

INTRODUCTION: This analysis evaluates the clinical and societal impact of increasing utilization of oral nirmatrelvir/ritonavir (NMV/r) for outpatient treatment of mild-to-moderate COVID-19 among high-risk adults in Spain. Despite strong evidence from clinical trials and real-world studies demonstrating NMV/r's effectiveness in reducing hospitalization …

il, us (code pays fourni par la source)

EE76 CLINICAL BENEFITS OF NIRMATRELVIR/RITONAVIR TREATMENT FOR COVID-19: A GLOBAL ECONOMIC VALUE SYSTEMATIC LITERATURE REVIEW

Tendai Mugwagwa, Jose Marcano Belisario, Louise Hartley, Nguyễn Duy Phan et autres

gb (code pays fourni par la source)

PCR172 POST-PANDEMIC BURDEN OF COVID-19 AMONG HIGH-RISK PATIENTS WITH ACUTE INFECTION: A CROSS-SECTIONAL SURVEY IN GERMANY

Mousumi Biswas, James Lucas, Tendai Mugwagwa, Eveline Otte im Kampe et autres

us, gb, de (code pays fourni par la source)

CO56 BASELINE (UNTREATED) RISK OF HOSPITALIZATION AND MORTALITY IN PATIENTS WITH SPECIFIC COMORBID HIGH-RISK CONDITIONS WHO ARE ELIGIBLE FOR NIRMATRELVIR/RITONAVIR TREATMENT: A SYSTEMATIC LITERATURE REVIEW EXPANSION STUDY

Tendai Mugwagwa, David Campbell, A Ajith, Nikolina Boskovic et autres